Form 4: DiaMedica Therapeutics Director Acquires Shares Through Deferred Stock Units
SEC Form 4
Director Randall Michael Giuffre acquired 10,861 shares of DiaMedica Therapeutics through the settlement of deferred stock units.
Summary
- On January 2, 2025, Randall Michael Giuffre, a director of DiaMedica Therapeutics Inc., acquired 10,861 shares of voting common stock at a price of $5.34 per share.
- These shares were obtained through the settlement of deferred stock units granted under the company's Amended and Restated 2019 Omnibus Incentive Plan.
- The deferred stock units are in lieu of cash retainer fees totaling $58,000 and will vest in four nearly equal installments throughout 2025.
- Following the transaction, Giuffre directly owns 375,412 shares and indirectly owns 25,573 shares through 424822 Albert Ltd and 21,070 shares held by his spouse.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard transaction; director acquiring shares through compensation.
Positives
- The director's acquisition of shares could be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
This is a routine disclosure of insider trading activity. It is common for directors to receive stock options or deferred stock units as part of their compensation.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment, reflecting confidence from a company director.
Key Dates
| Date | Description |
|---|---|
| 01/02/2025 | Date of transaction: Director acquired shares through deferred stock units. |
| 01/03/2025 | Date of signature on the Form 4 filing. |
| 03/31/2025 | First vesting date for deferred stock units. |
| 06/30/2025 | Second vesting date for deferred stock units. |
| 09/30/2025 | Third vesting date for deferred stock units. |
| 12/31/2025 | Final vesting date for deferred stock units. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.